This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
In the June 7, 1958, issue of The Journal, page 735, an article entitled "Current Status of Therapy in Anemias," by Lichtman, states that parenterally administered iron, for example, in the form of an iron-dextran complex (Imferon) in great excesses over a long period of time will produce "exogenous hemochromatosis." Since parenteral therapy with properly calculated dosage of iron-dextran complex should be discontinued when a hematological response has been obtained, as well as when this type of therapy fails or the patient eventually becomes anemic, iron-storage diseases, i. e., hemosiderosis or hemochromatosis, should not occur under these circumstances, because the possibility of iron overload is eliminated. The subject of iron-overload has been discussed in a textbook, "Iron in Clinical Medicine" (edited by Wallerstein and Mettier, Berkeley, University of California Press, 1958). The question of whether hemosiderosis progresses to hemochromatosis has been answered both affirmatively and negatively. Much
Kleckner MS. THERAPY IN THE ANEMIAS. JAMA. 1959;169(13):1510. doi:10.1001/jama.1959.03000300106022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: